Tag: GlobeNewswire

BioSummer Dental adds NextDent® 300 MultiJet 3D printers to its distribution portfolio, supporting broader access to digital denture production across France

ROCK HILL, S.C., Nov. 02, 2026 (GLOBE NEWSWIRE) — 3D Systems (NYSE: DDD) today announced an expansion of its long-standing strategic distribution partnership with BioSummer Dental, a France-based distributor of advanced digital dentistry solutions. As part of the collaboration, BioSummer Dental has added the NextDent 300 MultiJet 3D printer to its portfolio and is preparing to deliver the first units to several strategic customers, reinforcing its commitment to bringing innovative dental 3D printing technologies to laboratories throughout Europe.

The expansion supports 3D Systems’ European growth strategy following the achievement of EU Medical Device Regulation (EU MDR 2017/745) certification in April 2026 for the NextDent Jet Base and Teeth materials, enabling commercialization throughout the European Union. With this critical milestone achieved, the Company is now expanding market access through strategic distribution partnerships and helping more dental laboratories transition to efficient, scalable digital denture production.

“Expanding our presence in Europe is a key priority for our dental business, and strong distribution partners like BioSummer Dental are essential to that growth,” said Jeff Graves, President and CEO of 3D Systems. “BioSummer Dental’s decision to add the NextDent 300 to its portfolio demonstrates their confidence in our technology and the opportunity ahead for digital denture production. We are pleased to strengthen this partnership as we work together to bring the benefits of the NextDent Jetted Denture Solution to more laboratories, and ultimately, more patients across Europe.”

The NextDent Jetted Denture Solution enables laboratories to produce highly aesthetic, durable monolithic dentures through a streamlined, integrated workflow. By simplifying production and reducing labor-intensive manual processes, the solution helps laboratories improve efficiency, increase productivity, and consistently deliver high-quality, patient-specific dentures.

Through its established presence in the dental industry and expertise in digital workflows, BioSummer Dental plays an important role in making these capabilities more accessible to dental professionals. The addition of the NextDent 300 positions BioSummer Dental to support broader adoption as laboratories seek more efficient solutions to meet growing production demands.

“We are excited to expand our partnership with 3D Systems and add the NextDent 300 to our distribution portfolio,” said Olivier Bellaton, CEO, BioSummer Dental. “Digital denture production represents a significant opportunity for dental laboratories across Europe. We believe the NextDent Jetted Denture Solution offers an exceptional combination of quality, productivity, and ease of use, and we look forward to helping our customers take advantage of this technology.”

Together, 3D Systems and BioSummer Dental aim to accelerate the adoption of digital denture workflows, making advanced manufacturing solutions more accessible to dental professionals across France and the rest of Europe.

For more information about the NextDent Jetted Denture Solution, visit www.3dsystems.com/dental-jetted-dentures.

About 3D Systems

For 40 years Chuck Hull’s curiosity and desire to improve the way products were designed and manufactured gave birth to 3D printing, 3D Systems, and the additive manufacturing industry. Since then, that same spark continues to ignite the 3D Systems team as we work side-by-side with our customers to change the way industries innovate. As a full-service solutions partner, we deliver industry-leading 3D printing technologies, materials and software to high-value markets such as medical and dental; aerospace, space and defense; transportation and motorsports; data center infrastructure; and durable goods. Each application-specific solution is powered by the expertise and passion of our employees who endeavor to achieve our shared goal of Transforming Manufacturing for a Better Future. More information on the company is available at www.3dsystems.com.

About BioSummer Dental BioSummer Dental is a France-based provider and distributor of digital dental technologies and solutions. With a focus on helping dental professionals adopt innovative manufacturing workflows, the company offers technologies designed to support productivity, precision, and efficiency in modern dental laboratories. For more information, visit www.biosummer.com.

Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the timing of product launches, regulatory approvals, market opportunities, expected revenue impact, and shareholder value. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not, be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

Investor Contact: investor.relations@3dsystems.com
Media Contact: press@3dsystems.com

BioSummer Dental adds NextDent® 300 MultiJet 3D printers to its distribution portfolio, supporting broader access to digital denture production across France

ROCK HILL, S.C., Nov. 02, 2026 (GLOBE NEWSWIRE) — 3D Systems (NYSE: DDD) today announced an expansion of its long-standing strategic distribution partnership with BioSummer Dental, a France-based distributor of advanced digital dentistry solutions. As part of the collaboration, BioSummer Dental has added the NextDent 300 MultiJet 3D printer to its portfolio and is preparing to deliver the first units to several strategic customers, reinforcing its commitment to bringing innovative dental 3D printing technologies to laboratories throughout Europe.

The expansion supports 3D Systems’ European growth strategy following the achievement of EU Medical Device Regulation (EU MDR 2017/745) certification in April 2026 for the NextDent Jet Base and Teeth materials, enabling commercialization throughout the European Union. With this critical milestone achieved, the Company is now expanding market access through strategic distribution partnerships and helping more dental laboratories transition to efficient, scalable digital denture production.

“Expanding our presence in Europe is a key priority for our dental business, and strong distribution partners like BioSummer Dental are essential to that growth,” said Jeff Graves, President and CEO of 3D Systems. “BioSummer Dental’s decision to add the NextDent 300 to its portfolio demonstrates their confidence in our technology and the opportunity ahead for digital denture production. We are pleased to strengthen this partnership as we work together to bring the benefits of the NextDent Jetted Denture Solution to more laboratories, and ultimately, more patients across Europe.”

The NextDent Jetted Denture Solution enables laboratories to produce highly aesthetic, durable monolithic dentures through a streamlined, integrated workflow. By simplifying production and reducing labor-intensive manual processes, the solution helps laboratories improve efficiency, increase productivity, and consistently deliver high-quality, patient-specific dentures.

Through its established presence in the dental industry and expertise in digital workflows, BioSummer Dental plays an important role in making these capabilities more accessible to dental professionals. The addition of the NextDent 300 positions BioSummer Dental to support broader adoption as laboratories seek more efficient solutions to meet growing production demands.

“We are excited to expand our partnership with 3D Systems and add the NextDent 300 to our distribution portfolio,” said Olivier Bellaton, CEO, BioSummer Dental. “Digital denture production represents a significant opportunity for dental laboratories across Europe. We believe the NextDent Jetted Denture Solution offers an exceptional combination of quality, productivity, and ease of use, and we look forward to helping our customers take advantage of this technology.”

Together, 3D Systems and BioSummer Dental aim to accelerate the adoption of digital denture workflows, making advanced manufacturing solutions more accessible to dental professionals across France and the rest of Europe.

For more information about the NextDent Jetted Denture Solution, visit www.3dsystems.com/dental-jetted-dentures.

About 3D Systems

For 40 years Chuck Hull’s curiosity and desire to improve the way products were designed and manufactured gave birth to 3D printing, 3D Systems, and the additive manufacturing industry. Since then, that same spark continues to ignite the 3D Systems team as we work side-by-side with our customers to change the way industries innovate. As a full-service solutions partner, we deliver industry-leading 3D printing technologies, materials and software to high-value markets such as medical and dental; aerospace, space and defense; transportation and motorsports; data center infrastructure; and durable goods. Each application-specific solution is powered by the expertise and passion of our employees who endeavor to achieve our shared goal of Transforming Manufacturing for a Better Future. More information on the company is available at www.3dsystems.com.

About BioSummer Dental BioSummer Dental is a France-based provider and distributor of digital dental technologies and solutions. With a focus on helping dental professionals adopt innovative manufacturing workflows, the company offers technologies designed to support productivity, precision, and efficiency in modern dental laboratories. For more information, visit www.biosummer.com.

Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the timing of product launches, regulatory approvals, market opportunities, expected revenue impact, and shareholder value. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not, be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

Investor Contact: investor.relations@3dsystems.com
Media Contact: press@3dsystems.com

Latest Collaboration Comes Amid Progress in Other Strategic Initiatives, Including Follow-on Investment in Earlier Minority Stake Investment Target

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced a strategic collaboration with Mindful Health Solutions (“MHS”), an established provider of comprehensive behavioral health and interventional psychiatry services. In August, Mindful Health Solutions’ managed services organization was acquired by Radial Health, Inc. The combined management company, operating under the Radial banner, now supports the largest network of brain medicine clinics in the US, operating 27 locations across California, Missouri, New York, South Carolina, Tennessee, Texas and Washington. 

The strategic collaboration aims to expand patient access to innovative, noninvasive mental health treatments including BrainsWay Deep TMS™ and the recently FDA-cleared accelerated SWIFT™ treatment protocol, as well as to explore opportunities to integrate Neurolief’s Proliv™Rx at-home neuromodulation therapy into broader patient care pathways.

In addition, the companies intend to build and facilitate physician education and clinical awareness through joint initiatives, including key opinion leader (KOL) programs, educational events, targeted outreach to healthcare professionals, and research into synergistic treatment approaches. The collaboration reflects a shared commitment to improving clinical outcomes and developing scalable models of care across both clinical and at-home settings.

“We are elated to collaborate with Mindful Health Solutions, an organization that shares our commitment to advancing interventional psychiatry and improving patient outcomes,” said Hadar Levy, Chief Executive Officer of BrainsWay. “We are proud to deepen our relationship with one of the country’s leaders in brain medicine research and real-world clinical operations. By combining our innovative technology and expanding neuromodulation portfolio with MHS’s clinical expertise, we see meaningful opportunities to accelerate the adoption of powerful existing therapies we currently offer as well as to potentially identify new treatment approaches.”

The collaboration comes after additional progress in BrainsWay’s broader strategic initiatives, including its recent follow-on equity investment of $0.8m in the management services organization servicing the Texas-based “Heading Health” clinic network.

These efforts reflect BrainsWay’s broader strategy of partnering with leading behavioral health providers to increase awareness and accelerate the growth of interventional psychiatry.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “targets,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Historical results or conclusions from scientific research and clinical do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure to realize anticipated synergies and other benefits of the proposed transaction; the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Latest Collaboration Comes Amid Progress in Other Strategic Initiatives, Including Follow-on Investment in Earlier Minority Stake Investment Target

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced a strategic collaboration with Mindful Health Solutions (“MHS”), an established provider of comprehensive behavioral health and interventional psychiatry services. In August, Mindful Health Solutions’ managed services organization was acquired by Radial Health, Inc. The combined management company, operating under the Radial banner, now supports the largest network of brain medicine clinics in the US, operating 27 locations across California, Missouri, New York, South Carolina, Tennessee, Texas and Washington. 

The strategic collaboration aims to expand patient access to innovative, noninvasive mental health treatments including BrainsWay Deep TMS™ and the recently FDA-cleared accelerated SWIFT™ treatment protocol, as well as to explore opportunities to integrate Neurolief’s Proliv™Rx at-home neuromodulation therapy into broader patient care pathways.

In addition, the companies intend to build and facilitate physician education and clinical awareness through joint initiatives, including key opinion leader (KOL) programs, educational events, targeted outreach to healthcare professionals, and research into synergistic treatment approaches. The collaboration reflects a shared commitment to improving clinical outcomes and developing scalable models of care across both clinical and at-home settings.

“We are elated to collaborate with Mindful Health Solutions, an organization that shares our commitment to advancing interventional psychiatry and improving patient outcomes,” said Hadar Levy, Chief Executive Officer of BrainsWay. “We are proud to deepen our relationship with one of the country’s leaders in brain medicine research and real-world clinical operations. By combining our innovative technology and expanding neuromodulation portfolio with MHS’s clinical expertise, we see meaningful opportunities to accelerate the adoption of powerful existing therapies we currently offer as well as to potentially identify new treatment approaches.”

The collaboration comes after additional progress in BrainsWay’s broader strategic initiatives, including its recent follow-on equity investment of $0.8m in the management services organization servicing the Texas-based “Heading Health” clinic network.

These efforts reflect BrainsWay’s broader strategy of partnering with leading behavioral health providers to increase awareness and accelerate the growth of interventional psychiatry.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “targets,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Historical results or conclusions from scientific research and clinical do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure to realize anticipated synergies and other benefits of the proposed transaction; the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Event: Guggenheim 3^rd Annual Healthcare Innovation Conference
Date: November 9-11, 2026
Fireside Date/Time: Monday, November 9^th at 9:00am ET

Event: Jefferies London Healthcare Conference
Date: November 16-19, 2026
Fireside Date/Time: Thursday, November 19^th at 1:00pm GMT

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Contacts:

Christen Baglaneas 
Rezolute, Inc. 
1411 Broadway, 16th Floor 
New York, NY 10018 
cbaglaneas@rezolutebio.com 
508-272-6717 

Carrie McKim 
Rezolute, Inc. 
1411 Broadway, 16th Floor 
New York, NY 10018 
cmckim@rezolutebio.com  
336-608-9706 

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Event: Guggenheim 3^rd Annual Healthcare Innovation Conference
Date: November 9-11, 2026
Fireside Date/Time: Monday, November 9^th at 9:00am ET

Event: Jefferies London Healthcare Conference
Date: November 16-19, 2026
Fireside Date/Time: Thursday, November 19^th at 1:00pm GMT

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Contacts:

Christen Baglaneas 
Rezolute, Inc. 
1411 Broadway, 16th Floor 
New York, NY 10018 
cbaglaneas@rezolutebio.com 
508-272-6717 

Carrie McKim 
Rezolute, Inc. 
1411 Broadway, 16th Floor 
New York, NY 10018 
cmckim@rezolutebio.com  
336-608-9706 

VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Trekor Metals Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (“Trekor” or the “Company”) will release its third quarter 2026 financial results after market close on Wednesday, November 4, 2026.

The Company will host a telephone conference call and live webcast on Thursday, November 5, 2026, at 11:00 a.m. Eastern Time to discuss these results. After opening remarks by management, there will be a question and answer session open to analysts and investors.

The conference call may be accessed by dialing 800-715-9871 toll free or 646-307-1963, using the access code 1263967.

The webcast may be accessed at https://trekormetals.com/investors/events/ and will be archived until November 5, 2027, for later playback.

For further information on Trekor, see the Company’s website at trekormetals.com or contact:

Brian Bergot, Vice President, Investor Relations – 778-373-4533 or toll-free 1-877-441-4533

Stuart McDonald
President and CEO

No regulatory authority has approved or disapproved of the information contained in this news release.

VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Trekor Metals Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (“Trekor” or the “Company”) will release its third quarter 2026 financial results after market close on Wednesday, November 4, 2026.

The Company will host a telephone conference call and live webcast on Thursday, November 5, 2026, at 11:00 a.m. Eastern Time to discuss these results. After opening remarks by management, there will be a question and answer session open to analysts and investors.

The conference call may be accessed by dialing 800-715-9871 toll free or 646-307-1963, using the access code 1263967.

The webcast may be accessed at https://trekormetals.com/investors/events/ and will be archived until November 5, 2027, for later playback.

For further information on Trekor, see the Company’s website at trekormetals.com or contact:

Brian Bergot, Vice President, Investor Relations – 778-373-4533 or toll-free 1-877-441-4533

Stuart McDonald
President and CEO

No regulatory authority has approved or disapproved of the information contained in this news release.

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poster presentation, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, held in collaboration with the American Heart Association Scientific Sessions, taking place in Chicago, IL, November 6, 2026.

Late-Breaking Oral Abstracts

Title: Effect of Aficamten on Cardiac Structure and Function in Nonobstructive Hypertrophic Cardiomyopathy: The ACACIA-HCM CMR Study
Presenter: Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: Friday, November 6, 2026
Session Title: Session 4 – Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:30 PM – 2:40 PM CT
Location: Room S406a

Title: Effect of Aficamten on Patient-Reported Health Status in Non-Obstructive Hypertrophic Cardiomyopathy
Presenter: Michael E. Nassif, M.D., Cardiologist, Saint Luke’s Mid America Heart Institute
Date: Friday, November 6, 2026
Session Title: Session 4 – Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:45 PM -2:55 PM CT
Location: Room S406A

Poster Presentation

Title: Left Ventricular Systolic Dysfunction in Long-Term Aficamten Therapy for Obstructive HCM: A FOREST-HCM Analysis
Presenter: Daniele Massera, M.D., Director, Hypertrophic Cardiomyopathy Program, NYU Langone Health, Assistant Professor, Department of Medicine, NYU Grossman School of Medicine
Date: November 6, 2026
Session Title: Poster Reception
Session Time: 5:30 PM – 6:30 PM CT
Presentation Time: 5:30 PM – 6:30 PM CT
Location: Room S406B

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any jurisdiction by any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten, or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poster presentation, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, held in collaboration with the American Heart Association Scientific Sessions, taking place in Chicago, IL, November 6, 2026.

Late-Breaking Oral Abstracts

Title: Effect of Aficamten on Cardiac Structure and Function in Nonobstructive Hypertrophic Cardiomyopathy: The ACACIA-HCM CMR Study
Presenter: Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: Friday, November 6, 2026
Session Title: Session 4 – Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:30 PM – 2:40 PM CT
Location: Room S406a

Title: Effect of Aficamten on Patient-Reported Health Status in Non-Obstructive Hypertrophic Cardiomyopathy
Presenter: Michael E. Nassif, M.D., Cardiologist, Saint Luke’s Mid America Heart Institute
Date: Friday, November 6, 2026
Session Title: Session 4 – Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:45 PM -2:55 PM CT
Location: Room S406A

Poster Presentation

Title: Left Ventricular Systolic Dysfunction in Long-Term Aficamten Therapy for Obstructive HCM: A FOREST-HCM Analysis
Presenter: Daniele Massera, M.D., Director, Hypertrophic Cardiomyopathy Program, NYU Langone Health, Assistant Professor, Department of Medicine, NYU Grossman School of Medicine
Date: November 6, 2026
Session Title: Poster Reception
Session Time: 5:30 PM – 6:30 PM CT
Presentation Time: 5:30 PM – 6:30 PM CT
Location: Room S406B

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any jurisdiction by any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten, or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757